Patients undergoing elective arthroscopic rotator cuff repair often face significant pain during the first few days of recovery. To address this, researchers are designing a study to see if a specific type of nerve block—the superior trunk block (STB)—can provide lasting relief without affecting how well patients can move their shoulders.
The trial will involve 282 adult patients. They will receive ultrasound-guided STB using liposomal bupivacaine at three different concentrations: 66 mg, 44 mg, or 33 mg. The goal is to determine which dose provides the best balance of pain relief and mobility over a 72-hour period.
Because this is currently a study protocol, no results have been gathered yet. The researchers are looking specifically at rest pain scores and how much morphine patients need after surgery. Once the trial is complete, the data will help doctors decide on the best way to manage patient comfort during recovery.
Common questions
What is being tested in this study?
The study is a protocol designed to test three different doses of liposomal bupivacaine (66 mg, 44 mg, and 33 mg) during an ultrasound-guided superior trunk block. Researchers want to see which dose best manages pain and reduces the need for morphine in patients undergoing rotator cuff surgery.
Who is eligible for this trial?
The study is designed for adult patients who are scheduled for elective arthroscopic rotator cuff repair. The goal is to provide effective, long-lasting pain relief while ensuring the patient can still move their shoulder properly during the first 72 hours after surgery.
Are there results available from this study yet?
No, because this is a trial protocol, it has not been conducted or reported yet. No data on pain scores, morphine use, or safety are currently available. You should speak with your doctor regarding current standard treatments for shoulder surgery pain.
